Implantica publishes Annual Report 2020
Implantica AG (publ) is publishing its annual report for the fiscal year 2020. The annual report is now available on the company’s website.
“2020 was a busy year for us at Implantica, fuelled by our successful move to the stock market in September 2020. The extraordinary three-year results of our clinical trial indicate that RefluxStop™ has a bright future ahead and the attributes to become the new standard of care in acid reflux treatment. We are also in an exciting phase with our new platform technologies and we foresee Implantica to be in the frontline of the eHealth revolution in the years to come”
- Peter Forsell, CEO and Founder of Implantica
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, email@example.com
The information was sent for publication, through the agency of the contact person set out above, on March 24, 2021 at 08:00 a.m. (CET).
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.